Stryker (SYK) 10-Q 27 Jul 22 2022 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information	6 Months Ended
	Jun. 30, 2022 shares
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2022
Document Transition Report	false
Entity File Number	001-13149
Entity Registrant Name	STRYKER CORP
Entity Incorporation, State or Country Code	MI
Entity Tax Identification Number	38-1239739
Entity Address, Address Line One	2825 Airview Boulevard
Entity Address, City or Town	Kalamazoo,
Entity Address, State or Province	MI
Entity Address, Postal Zip Code	49002
City Area Code	(269)
Local Phone Number	385-2600
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding	378,320,706
Amendment Flag	false
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Entity Central Index Key	0000310764
Current Fiscal Year End Date	--12-31
Common Stock
Document Information [Line Items]
Title of each class	Common Stock, $.10 Par Value
Trading Symbol	SYK
Security Exchange Name	NYSE
Senior Unsecured Notes 1.125% due 2021
Document Information [Line Items]
Title of each class	1.125% Notes due 2023
Trading Symbol	SYK23
Security Exchange Name	NYSE
Senior Unsecured Notes, 0.250% Due 2024
Document Information [Line Items]
Title of each class	0.250% Notes due 2024
Trading Symbol	SYK24A
Security Exchange Name	NYSE
Senior Unsecured Notes 2.125% due 2027
Document Information [Line Items]
Title of each class	2.125% Notes due 2027
Trading Symbol	SYK27
Security Exchange Name	NYSE
Senior Unsecured Notes, 0.750% Due 2029
Document Information [Line Items]
Title of each class	0.750% Notes due 2029
Trading Symbol	SYK29
Security Exchange Name	NYSE
Senior Unsecured Notes 2.625% due 2030
Document Information [Line Items]
Title of each class	2.625% Notes due 2030
Trading Symbol	SYK30
Security Exchange Name	NYSE
Senior Unsecured Notes, 1.000% Due 2031
Document Information [Line Items]
Title of each class	1.000% Notes due 2031
Trading Symbol	SYK31
Security Exchange Name	NYSE

CONSOLIDATED STATEMENTS OF EARN

CONSOLIDATED STATEMENTS OF EARNINGS (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Statement [Abstract]
Net sales	$ 4,493	$ 4,294	$ 8,768	$ 8,247
Cost of sales	1,667	1,522	3,208	2,966
Gross profit	2,826	2,772	5,560	5,281
Research, development and engineering expenses	351	310	764	598
Selling, general and administrative expenses	1,539	1,505	3,249	3,080
Recall charges	4	76	18	82
Amortization of intangible assets	160	149	310	330
Total operating expenses	2,054	2,040	4,341	4,090
Operating income	772	732	1,219	1,191
Other income (expense), net	(52)	(70)	(113)	(162)
Earnings before income taxes	720	662	1,106	1,029
Income taxes	64	70	127	135
Net earnings	$ 656	$ 592	$ 979	$ 894
Net earnings per share of common stock:
Basic	$ 1.73	$ 1.57	$ 2.59	$ 2.37
Diluted	$ 1.72	$ 1.55	$ 2.56	$ 2.34
Weighted-average shares outstanding (in millions):
Basic	378.3	376.9	378	376.6
Effect of dilutive employee stock compensation	3.9	5.4	4.5	5.4
Diluted	382.2	382.3	382.5	382
Cash dividends declared per share of common stock (in dollars per share)	$ 0.695	$ 0.63	$ 1.39	$ 1.26

CONSOLIDATED STATEMENTS OF EA_2

CONSOLIDATED STATEMENTS OF EARNINGS (Unaudited)(Parenthetical) - shares shares in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Statement [Abstract]
Anti-dilutive shares excluded from calculation of dilutive employee stock options (in shares)	4.5	0	0	0

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Statement of Comprehensive Income [Abstract]
Net earnings	$ 656	$ 592	$ 979	$ 894
Other comprehensive income (loss), net of tax:
Marketable securities	0	0	(1)	0
Pension plans	8	(4)	7	3
Unrealized gains (losses) on designated hedges	24	8	25	36
Financial statement translation	161	(80)	214	175
Total other comprehensive income (loss), net of tax	193	(76)	245	214
Comprehensive income	$ 849	$ 516	$ 1,224	$ 1,108

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Jun. 30, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents	$ 1,044	$ 2,944
Marketable securities	83	75
Accounts receivable, less allowance of $144 ($167 in 2021)	3,145	3,022
Inventories:
Materials and supplies	790	691
Work in process	315	264
Finished goods	2,644	2,359
Total inventories	3,749	3,314
Prepaid expenses and other current assets	804	662
Total current assets	8,825	10,017
Property, plant and equipment:
Land, buildings and improvements	1,662	1,656
Machinery and equipment	3,887	3,842
Total property, plant and equipment	5,549	5,498
Less accumulated depreciation	2,746	2,665
Property, plant and equipment, net	2,803	2,833
Goodwill	15,115	12,918
Other intangibles, net	5,245	4,840
Noncurrent deferred income tax assets	1,625	1,760
Other noncurrent assets	2,419	2,263
Total assets	36,032	34,631
Current liabilities
Accounts payable	1,160	1,129
Accrued compensation	779	1,092
Income taxes	300	192
Dividends payable	263	263
Accrued product liabilities	400	401
Accrued expenses and other liabilities	1,495	1,465
Current maturities of debt	7	7
Total current liabilities	4,404	4,549
Long-term debt, excluding current maturities	13,374	12,472
Income taxes	787	913
Other noncurrent liabilities	1,793	1,820
Total liabilities	20,358	19,754
Shareholders' equity
Common stock, $0.10 par value	38	38
Additional paid-in capital	1,989	1,890
Retained earnings	13,933	13,480
Accumulated other comprehensive loss	(286)	(531)
Total shareholders' equity	15,674	14,877
Total liabilities and shareholders' equity	$ 36,032	$ 34,631
Common stock, par value (in dollars per share)	$ 0.10	$ 0.10

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Millions	Jun. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Allowance for doubtful accounts receivable	$ 144	$ 167
Common stock, par value (in dollars per share)	$ 0.10	$ 0.10

CONSOLIDATED STATEMENTS OF SHAR

CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (Unaudited) - USD ($) shares in Millions, $ in Millions	Total	Common Stock	Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)
Beginning balance at Dec. 31, 2020		$ 38	$ 1,741	$ 12,462	$ (1,157)
Beginning balance (in shares) at Dec. 31, 2020		376.1
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under stock compensation and benefit plans			(4)
Issuance of common stock under stock option and benefit plans (in shares)		1
Share-based compensation			107
Net earnings	$ 894			894
Cash dividends declared				(475)
Other comprehensive income (loss)	214				214
Ending balance at Jun. 30, 2021	13,820	$ 38	1,844	12,881	(943)
Ending balance (in shares) at Jun. 30, 2021		377.1
Beginning balance at Mar. 31, 2021		$ 38	1,806	12,525	(867)
Beginning balance (in shares) at Mar. 31, 2021		376.7
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under stock compensation and benefit plans		$ 0	(1)
Issuance of common stock under stock option and benefit plans (in shares)		0.4
Share-based compensation			39
Net earnings	592			592
Cash dividends declared				(236)
Other comprehensive income (loss)	(76)				(76)
Ending balance at Jun. 30, 2021	13,820	$ 38	1,844	12,881	(943)
Ending balance (in shares) at Jun. 30, 2021		377.1
Beginning balance at Dec. 31, 2021	14,877	$ 38	1,890	13,480	(531)
Beginning balance (in shares) at Dec. 31, 2021		377.5
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under stock compensation and benefit plans		$ 0	(8)
Issuance of common stock under stock option and benefit plans (in shares)		0.8
Share-based compensation			107
Net earnings	979			979
Cash dividends declared				(526)
Other comprehensive income (loss)	245				245
Ending balance at Jun. 30, 2022	15,674	$ 38	1,989	13,933	(286)
Ending balance (in shares) at Jun. 30, 2022		378.3
Beginning balance at Mar. 31, 2022		$ 38	1,947	13,540	(479)
Beginning balance (in shares) at Mar. 31, 2022		378.2
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under stock compensation and benefit plans		$ 0	6
Issuance of common stock under stock option and benefit plans (in shares)		0.1
Share-based compensation			36
Net earnings	656			656
Cash dividends declared				(263)
Other comprehensive income (loss)	193				193
Ending balance at Jun. 30, 2022	$ 15,674	$ 38	$ 1,989	$ 13,933	$ (286)
Ending balance (in shares) at Jun. 30, 2022		378.3

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Operating activities
Net earnings	$ 979	$ 894
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation	185	187
Amortization of intangible assets	310	330
Asset impairments	0	3
Share-based compensation	107	107
Recall charges	18	82
Sale of inventory stepped-up to fair value at acquisition	12	137
Changes in operating assets and liabilities:
Accounts receivable	(159)	(24)
Inventories	(523)	(128)
Accounts payable	34	57
Accrued expenses and other liabilities	(257)	22
Recall-related payments	(19)	(163)
Income taxes	(132)	(98)
Other, net	177	(76)
Net cash provided by operating activities	732	1,330
Investing activities
Acquisitions, net of cash acquired	(2,563)	(104)
Purchases of marketable securities	(38)	(31)
Proceeds from sales of marketable securities	29	28
Purchases of property, plant and equipment	(262)	(189)
Other investing, net	0	(2)
Net cash used in investing activities	(2,834)	(298)
Financing activities
Proceeds (payments) on short-term borrowings, net	(376)	(7)
Proceeds from issuance of long-term debt	1,500	5
Payments on long-term debt	(252)	(1,151)
Payments of dividends	(525)	(475)
Cash paid for taxes from withheld shares	(84)	(74)
Other financing, net	(23)	(27)
Net cash provided by (used in) financing activities	240	(1,729)
Effect of exchange rate changes on cash and cash equivalents	(38)	(5)
Change in cash and cash equivalents	(1,900)	(702)
Cash and cash equivalents at beginning of period	2,944	2,943
Cash and cash equivalents at end of period	$ 1,044	$ 2,241

Basis Of Presentation

Basis Of Presentation	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	BASIS OF PRESENTATION General Information Management believes the accompanying unaudited Consolidated Financial Statements contain all adjustments, including normal recurring items, considered necessary to fairly present the financial position of Stryker Corporation and its consolidated subsidiaries ("Stryker," the "Company," "we," "us" or "our") on June 30, 2022 a nd the results of operations for the three and six months 2022. The results of operations included in these Consolidated Financial Statements may not necessarily be indicative of our annual results. These statements should be read in conjunction with our Annual Report on Form 10-K for 2021. New Accounting Pronouncements Not Yet Adopted We evaluate all Accounting Standards Updates (ASUs) issued by the Financial Accounting Standards Board (FASB) for consideration of their applicability. ASUs not included in our disclosures were assessed and determined to be either not applicable or are not expected to have a material impact on our Consolidated Financial Statements. New Accounting Pronouncements Recently Adopted On January 1, 2022 we adopted ASU 2021-08, Business Combinations: Accounting for Contract Assets and Contract Liabilities from Contracts with Customers . This update requires an entity to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Accounting Standards Codification 606, Revenue from Contracts with Customers . The adoption of this update did not have a material impact on our Consolidated Financial Statements.

Revenue Recognition

Revenue Recognition	6 Months Ended
	Jun. 30, 2022
Revenue Recognition [Abstract]
Revenue Recognition	REVENUE RECOGNITION Our policies for recognizing sales have not changed from those described in our Annual Report on Form 10-K for 2021. We disaggregate our net sales by product line and geographic location for each of our segments as we believe it best depicts how the nature, amount, timing and certainty of our net sales and cash flows are affected by economic factors. Net Sales by Product Line Three Months Six Months 2022 2021 2022 2021 MedSurg and Neurotechnology: Instruments $ 563 $ 517 $ 1,091 $ 986 Endoscopy 600 518 1,138 987 Medical 666 640 1,330 1,262 Neurovascular 306 301 607 590 Neuro Cranial 337 310 660 591 Other 77 73 146 134 $ 2,549 $ 2,359 $ 4,972 $ 4,550 Orthopaedics and Spine: Knees $ 500 $ 474 $ 964 $ 886 Hips 364 353 691 662 Trauma and Extremities 676 674 1,361 1,314 Spine 290 307 569 585 Other 114 127 211 250 $ 1,944 $ 1,935 $ 3,796 $ 3,697 Total $ 4,493 $ 4,294 $ 8,768 $ 8,247 Net Sales by Geography Three Months 2022 Three Months 2021 United States International United States International MedSurg and Neurotechnology: Instruments $ 451 $ 112 $ 401 $ 116 Endoscopy 473 127 407 111 Medical 536 130 488 152 Neurovascular 113 193 115 186 Neuro Cranial 281 56 256 54 Other 75 2 72 1 $ 1,929 $ 620 $ 1,739 $ 620 Orthopaedics and Spine: Knees $ 368 $ 132 $ 349 $ 125 Hips 230 134 221 132 Trauma and Extremities 489 187 475 199 Spine 209 81 217 90 Other 86 28 99 28 $ 1,382 $ 562 $ 1,361 $ 574 Total $ 3,311 $ 1,182 $ 3,100 $ 1,194 Net Sales by Geography Six Months 2022 Six Months 2021 United States International United States International MedSurg and Neurotechnology: Instruments $ 865 $ 226 $ 756 $ 230 Endoscopy 891 247 761 226 Medical 1,061 269 961 301 Neurovascular 223 384 226 364 Neuro Cranial 545 115 480 111 Other 143 3 132 2 $ 3,728 $ 1,244 $ 3,316 $ 1,234 Orthopaedics and Spine: Knees $ 713 $ 251 $ 643 $ 243 Hips 432 259 407 255 Trauma and Extremities 976 385 915 399 Spine 409 160 410 175 Other 158 53 193 57 $ 2,688 $ 1,108 $ 2,568 $ 1,129 Total $ 6,416 $ 2,352 $ 5,884 $ 2,363 Contract Assets and Liabilities On June 30, 2022 and December 31, 2021 contract assets recorded in our Consolidated Balance Sheets were not significant.

Accumulated Other Comprehensive

Accumulated Other Comprehensive (Loss) Income (AOCI)	6 Months Ended
	Jun. 30, 2022
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Accumulated Other Comprehensive (Loss) Income (AOCI)	ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME (AOCI) Three Months 2022 Marketable Securities Pension Plans Hedges Financial Statement Translation Total Beginning $ (1) $ (156) $ 41 $ (363) $ (479) OCI — 8 32 268 308 Income taxes — (2) (4) (98) (104) Reclassifications to: Cost of sales — — (3) — (3) Other (income) expense — 2 (1) (11) (10) Income taxes — — — 2 2 Net OCI $ — $ 8 $ 24 $ 161 $ 193 Ending $ (1) $ (148) $ 65 $ (202) $ (286) Three Months 2021 Marketable Securities Pension Plans Hedges Financial Statement Translation Total Beginning $ (3) $ (252) $ 18 $ (630) $ (867) OCI — (9) 7 (75) (77) Income taxes — 2 (3) 2 1 Reclassifications to: Cost of sales — — 4 — 4 Other (income) expense — 4 (1) (9) (6) Income taxes — (1) 1 2 2 Net OCI $ — $ (4) $ 8 $ (80) $ (76) Ending $ (3) $ (256) $ 26 $ (710) $ (943) Six Months 2022 Marketable Securities Pension Plans Hedges Financial Statement Translation Total Beginning $ — $ (155) $ 40 $ (416) $ (531) OCI (1) 4 36 354 393 Income taxes — — (6) (123) (129) Reclassifications to: Cost of sales — — (3) — (3) Other (income) expense — 4 (2) (22) (20) Income taxes — (1) — 5 4 Net OCI $ (1) $ 7 $ 25 $ 214 $ 245 Ending $ (1) $ (148) $ 65 $ (202) $ (286) Six Months 2021 Marketable Securities Pension Plans Hedges Financial Statement Translation Total Beginning $ (3) $ (259) $ (10) $ (885) $ (1,157) OCI — (1) 34 198 231 Income taxes — (2) (11) (10) (23) Reclassifications to: Cost of sales — — 5 — 5 Other (income) expense — 8 9 (17) — Income taxes — (2) (1) 4 1 Net OCI $ — $ 3 $ 36 $ 175 $ 214 Ending $ (3) $ (256) $ 26 $ (710) $ (943)

Derivative Instruments

Derivative Instruments	6 Months Ended
	Jun. 30, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments	DERIVATIVE INSTRUMENTSWe use operational and economic hedges, foreign currency exchange forward contracts, net investment hedges (both derivative and non-derivative financial instruments) and interest rate derivative instruments to manage the impact of currency exchange and interest rate fluctuations on earnings, cash flow and equity. We do not enter into derivative instruments for speculative purposes. We are exposed to potential credit loss in the event of nonperformance by our counterparties on our outstanding derivative instruments but do not anticipate nonperformance by any of our counterparties. Should a counterparty default, our maximum loss exposure is the asset balance of the instrument. We have not changed our hedging strategies, accounting practices or objectives from those disclosed in our Annual Report on Form 10-K for 2021. Foreign Currency Hedges June 2022 Cash Flow Net Investment Non-Designated Total Gross notional amount $ 676 $ 1,578 $ 5,194 $ 7,448 Maximum term in years 4.4 Fair value: Other current assets $ 36 $ — $ 158 $ 194 Other noncurrent assets 2 150 — 152 Other current liabilities (4) — (10) (14) Total fair value $ 34 $ 150 $ 148 $ 332 December 2021 Cash Flow Net Investment Non-Designated Total Gross notional amount $ 973 $ 2,266 $ 5,512 $ 8,751 Maximum term in years 4.9 Fair value: Other current assets $ 15 $ 39 $ 92 $ 146 Other noncurrent assets 1 65 — 66 Other current liabilities (7) — (10) (17) Total fair value $ 9 $ 104 $ 82 $ 195 We had €1.5 billion and €2.0 billion on June 30, 2022 and December 31, 2021 of certain foreign currency forward contracts designated as net investment hedges to hedge a portion of our investments in certain of our entities with functional currencies denominated in Euros. In addition to these derivative financial instruments designated as net investment hedges, we had €4.4 billion on June 30, 2022 and December 31, 2021 of senior unsecured notes designated as net investment hedges to selectively hedge portions of our investment in certain international subsidiaries. The currency effects of our Euro-denominated senior unsecured notes are reflected in AOCI within shareholders' equity where they offset gains and losses recorded on our net investment in international subsidiaries. On June 30, 2022 the total after tax gain (loss) in AOCI related to designated net investment hedges was $254. Net Currency Exchange Rate Gains (Losses) Derivative Three Months Six Months instrument: Recorded in: 2022 2021 2022 2021 Cash Flow Cost of sales $ 3 $ (4) $ 3 $ (5) Net Investment Other income (expense), net 11 9 22 17 Non-Designated Other income (expense), net 2 1 3 (1) Total $ 16 $ 6 $ 28 $ 11 Pretax gains (losses) on derivatives designated as cash flow hedges of $38 and net investment hedges of $32 recorded in AOCI are expected to be reclassified to cost of sales and other income (expense), net in earnings within 12 months as of June 30, 2022. This cash flow hedge reclassification is primarily due to the sale of inventory that includes previously hedged purchases. A component of the AOCI amounts related to net investment hedges is reclassified over the life of the hedge instruments as we elected to exclude the initial value of the component related to the spot-forward difference from the effectiveness assessment. Interest Rate Hedges Pretax gains of $5 recorded in AOCI related to other interest rate hedges closed in conjunction with debt issuances are expected to be reclassified to other income (expense), net in earnings within 12 months of June 30, 2022. The cash flow effect of interest rate hedges is recorded in cash flow from operations.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	FAIR VALUE MEASUREMENTS Our policies for managing risk related to foreign currency, interest rates, credit and markets and our process for determining fair value have not changed from those described in our Annual Report on Form 10-K for 2021. There were no significant transfers into or out of any level of the fair value hierarchy in 2022. Assets Measured at Fair Value June December 2022 2021 Cash and cash equivalents $ 1,044 $ 2,944 Trading marketable securities 160 193 Level 1 - Assets $ 1,204 $ 3,137 Available-for-sale marketable securities: Corporate and asset-backed debt securities $ 47 $ 48 Foreign government debt securities 2 2 United States agency debt securities 4 5 United States Treasury debt securities 27 19 Certificates of deposit 3 1 Total available-for-sale marketable securities $ 83 $ 75 Foreign currency exchange forward contracts 346 212 Level 2 - Assets $ 429 $ 287 Total assets measured at fair value $ 1,633 $ 3,424 Liabilities Measured at Fair Value June December 2022 2021 Deferred compensation arrangements $ 160 $ 193 Level 1 - Liabilities $ 160 $ 193 Foreign currency exchange forward contracts $ 14 $ 17 Level 2 - Liabilities $ 14 $ 17 Contingent consideration: Beginning $ 306 $ 393 Additions 1 62 Change in estimate (27) (1) Settlements (24) (148) Ending $ 256 $ 306 Level 3 - Liabilities $ 256 $ 306 Total liabilities measured at fair value $ 430 $ 516 Fair Value of Available for Sale Securities by Maturity June 2022 December 2021 Due in one year or less $ 52 $ 36 Due after one year through three years $ 31 $ 39 On June 30, 2022 and December 31, 2021 the aggregate difference between the cost and fair value of available-for-sale marketable securities was nominal. Interest and marketable securities income was $20 and $18 in the three months and $35 and $35 in the six months 2022 and 2021, which was recorded in other income (expense), net.

Contingencies and Commitments

Contingencies and Commitments	6 Months Ended
	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Contingencies and Commitments	CONTINGENCIES AND COMMITMENTSWe are involved in various ongoing proceedings, legal actions and claims arising in the normal course of business, including proceedings related to product, labor, intellectual property and other matters, the most significant of which are more fully described below. The outcomes of these matters will generally not be known for prolonged periods of time. In certain of the legal proceedings the claimants seek damages as well as other compensatory and equitable relief that could result in the payment of significant claims and settlements and/or the imposition of injunctions or other equitable relief. For legal matters for which management had sufficient information to reasonably estimate our future obligations, a liability representing management's best estimate of the probable loss, or the minimum of the range of probable losses when a best estimate within the range is not known, is recorded. The estimates are based on consultation with legal counsel, previous settlement experience and settlement strategies. If actual outcomes are less favorable than those estimated by management, additional expense may be incurred, which could unfavorably affect future operating results. We are self-insured for certain claims and expenses. The ultimate cost to us with respect to product liability claims could be materially different than the amount of the current estimates and accruals and could have a material adverse effect on our financial position, results of operations and cash flows. In April 2022 the United States District Court for the District of Delaware issued a judgment following a jury verdict in favor of PureWick Corporation (PureWick) for its 2019 complaint seeking patent infringement damages related to our PrimaFit and PrimoFit products. The court awarded damages and we recorded charges of $28 in March 2022. In June 2022 PureWick filed a motion to seek enhancement of the judgment and if successful, the judgment could total approximately $100 and include an injunction against future sales. We intend to appeal the outcome of this case. Recall Matters In June 2012 we voluntarily recalled our Rejuvenate and ABG II Modular-Neck hip stems and terminated global distribution of these hip products. Product liability lawsuits relating to this voluntary recall have been filed against us. In November 2014 we entered into a settlement agreement to compensate eligible United States patients who had revision surgery prior to November 3, 2014 and in December 2016 the settlement program was extended to patients who had revision surgery prior to December 19, 2016. In September 2020 we entered into a second settlement agreement to compensate eligible United States patients who had revision surgery prior to September 9, 2020. We continue to offer support for recall-related care and reimburse patients who are not eligible to enroll in the settlement program for testing and treatment services, including any necessary revision surgeries. In addition, there are remaining lawsuits that we will continue to defend against. In August 2016 and May 2018 we voluntarily recalled certain lot-specific sizes and offsets of LFIT Anatomic CoCr V40 Femoral Heads. Product liability lawsuits and claims relating to this voluntary recall have been filed against us. In November 2018 we entered into a settlement agreement to resolve a significant number of claims and lawsuits related to the recalls. In April 2022 we executed a second agreement to resolve a significant number of claims and lawsuits related to the recalls. The specific terms of the settlement agreement, including the financial terms, are confidential. With the acquisition of Wright Medical Group N.V. (Wright) in November 2020, we are responsible for certain product liability claims, primarily related to certain hip products sold by Wright prior to its 2014 divestiture of the OrthoRecon business. We will continue to evaluate each claim and the possible loss we may incur. We have incurred, and expect to incur in the future, costs associated with the defense and settlement of these matters. For the six months 2022 we have recorded charges of $18 primarily related to Wright hip products and made payments of $19 primarily related to Rejuvenate and ABG II Modular-Neck hip stems. Based on the information that has been received, we have estimated the remaining range of probable loss related to recall matters globally to be approximately $380 to $515. We have recorded reserves representing the remaining minimum of the range of probable loss. The final outcomes of these matters are dependent on many factors that are difficult to predict. Accordingly the ultimate cost related to these matters may be materially different than the amount of our current estimate and accruals and could have a material adverse effect on our results of operations and cash flows. Leases June December 2022 2021 Right-of-use assets $ 469 $ 419 Lease liabilities, current $ 118 $ 112 Lease liabilities, non-current $ 353 $ 310 Other information: Weighted-average remaining lease term 5.6 years 5.4 years Weighted-average discount rate 2.66 % 2.86 % Three Months Six Months 2022 2021 2022 2021 Operating lease cost $ 38 $ 31 $ 73 $ 67

Acquisitions

Acquisitions	6 Months Ended
	Jun. 30, 2022
Business Combinations [Abstract]
Acquisitions	ACQUISITIONS We acquire stock in companies and various assets that continue to support our capital deployment and product development strategies. The aggregate purchase price of our acquisitions, net of cash acquired was $2,563 and $108 in the six months 2022 and 2021. In February 2022 we completed the acquisition of Vocera Communications, Inc. (Vocera) for $79.25 per share, or an aggregate purchase price of $2.6 billion, net of cash acquired ($3.0 billion including convertible notes). Vocera is a leader in the digital care coordination and communication category. Vocera is part of our Medical business within MedSurg and Neurotechnology. Goodwill attributable to the acquisition reflects the strategic benefits of expanding our presence in adjacent markets, diversifying our product portfolio, advancing innovations, and accelerating our digital aspirations. This goodwill is not deductible for tax purposes . In the six months 2022 note holders elected to redeem the 1.50% and 0.50% convertible notes assumed in the Vocera acquisition for $101 and $324. These repayments are classified as financing activities in the Consolidated Statements of Cash Flows. Share-based awards for Vocera employees vested upon our acquisition and a charge of $132 was recorded in selling, general and administrative expenses in 2022. Purchase price allocations for our significant acquisitions are: Purchase Price Allocation of Acquired Net Assets 2022 Vocera Tangible assets and liabilities: Accounts receivable $ 33 Inventory 13 Deferred income tax assets 73 Other assets 92 Debt (425) Deferred income tax liabilities (182) Other liabilities (115) Intangible assets: Customer and distributor relationships 550 Developed technology and patents 178 Trade name 18 Goodwill 2,328 Purchase price, net of cash acquired of $281 $ 2,563 Weighted-average life of intangible assets 13 Purchase price allocations for Vocera were based on preliminary valuations, primarily related to intangible assets and deferred income taxes. Our estimates and assumptions are subject to change within the measurement period. Consolidated Estimated Amortization Expense Remainder of 2022 2023 2024 2025 2026 $ 320 $ 620 $ 590 $ 570 $ 513

Debt and Credit Facilities

Debt and Credit Facilities	6 Months Ended
	Jun. 30, 2022
Long-term Debt, Unclassified [Abstract]
Debt And Credit Facilities	DEBT AND CREDIT FACILITIES We have lines of credit issued by various financial institutions that are available to fund our day-to-day operating needs. Certain of our credit facilities require us to comply with financial and other covenants. We were in compliance with all covenants on June 30, 2022. In February 2022 we entered into a $1.5 billion term loan agreement that matures on February 22, 2025 and bears interest at a base rate based on the Term Secured Overnight Financing Rate (SOFR) plus 0.725%. In June 2022 we repaid $250 on the term loan. In 2022 our Board of Directors approved an increase to the maximum amount of commercial paper that can be outstanding from $1,500 to $2,250. On June 30, 2022 there were no borrowings outstanding under our credit facility or commercial paper program which allows for maturities up to 397 days from the date of issuance. Summary of Total Debt June 2022 December 2021 Rate Due Senior unsecured notes: 1.125% November 30, 2023 $ 577 $ 622 0.600% December 1, 2023 598 598 3.375% May 15, 2024 595 593 0.250% December 3, 2024 890 958 1.150% June 15, 2025 646 645 3.375% November 1, 2025 748 748 3.500% March 15, 2026 994 994 2.125% November 30, 2027 784 845 3.650% March 7, 2028 597 597 0.750% March 1, 2029 836 901 1.950% June 15, 2030 990 990 2.625% November 30, 2030 675 727 1.000% December 3, 2031 779 840 4.100% April 1, 2043 392 392 4.375% May 15, 2044 395 395 4.625% March 15, 2046 982 982 2.900% June 15, 2050 642 642 Term loan February 22, 2025 1,250 — Other 11 10 Total debt $ 13,381 $ 12,479 Less current maturities of debt 7 7 Total long-term debt $ 13,374 $ 12,472 June 2022 December 2021 Unamortized debt issuance costs $ 57 $ 62 Borrowing capacity on existing facilities $ 2,162 $ 2,162 Fair value of senior unsecured notes $ 11,122 $ 13,391

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2022
Income Tax [Abstract]
Income Taxes	INCOME TAXES Our effective tax rates of 8.9% and 11.5% in the three and six months 2022 include the reversal of deferred income tax on undistributed earnings of foreign subsidiaries determined to be indefinitely reinvested and certain discrete tax items. Our effective tax rates of 10.6% and 13.1% in the three and six months 2021 include certain discrete tax items. We are routinely audited by income tax authorities in the jurisdictions we operate. In July 2022 we effectively settled the United States federal income tax audit for years 2014 through 2018. Accordingly in the three months ending September 30, 2022 we expect to reduce our accruals for uncertain tax positions and related interest by approximately $220.

Segment Information

Segment Information	6 Months Ended
	Jun. 30, 2022
Segment Reporting [Abstract]
Segment Information	SEGMENT INFORMATION As previously disclosed, effective December 31, 2021 we changed our reportable business segments to (i) MedSurg and Neurotechnology and (ii) Orthopaedics and Spine to align to our new internal reporting structure. We have reflected these changes in all historical periods presented. Three Months Six Months 2022 2021 2022 2021 MedSurg and Neurotechnology $ 2,549 $ 2,359 $ 4,972 $ 4,550 Orthopaedics and Spine 1,944 1,935 3,796 3,697 Net sales $ 4,493 $ 4,294 $ 8,768 $ 8,247 MedSurg and Neurotechnology $ 601 $ 702 $ 1,212 $ 1,337 Orthopaedics and Spine 607 563 1,129 1,018 Segment operating income $ 1,208 $ 1,265 $ 2,341 $ 2,355 Items not allocated to segments: Corporate and other $ (145) $ (154) $ (344) $ (316) Acquisition and integration-related costs (37) (120) (186) (369) Amortization of intangible assets (160) (149) (310) (330) Restructuring-related and other charges (62) (17) (171) (31) Medical device regulations (32) (26) (60) (45) Recall-related matters (4) (76) (18) (82) Regulatory and legal matters 4 9 (33) 9 Consolidated operating income $ 772 $ 732 $ 1,219 $ 1,191 There w ere no significant changes to total assets by segment from information provided in our Annual Report on Form 10-K for 2021, other than the addition of the assets acquired in the Vocera acquisition which are included in the MedSurg and Neurotechnology segment.

Basis Of Presentation (Policies

Basis Of Presentation (Policies)	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
New Accounting Pronouncements	New Accounting Pronouncements Not Yet Adopted We evaluate all Accounting Standards Updates (ASUs) issued by the Financial Accounting Standards Board (FASB) for consideration of their applicability. ASUs not included in our disclosures were assessed and determined to be either not applicable or are not expected to have a material impact on our Consolidated Financial Statements. New Accounting Pronouncements Recently Adopted On January 1, 2022 we adopted ASU 2021-08, Business Combinations: Accounting for Contract Assets and Contract Liabilities from Contracts with Customers . This update requires an entity to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Accounting Standards Codification 606, Revenue from Contracts with Customers . The adoption of this update did not have a material impact on our Consolidated Financial Statements.

Revenue Recognition (Tables)

Revenue Recognition (Tables)	6 Months Ended
	Jun. 30, 2022
Revenue Recognition [Abstract]
Schedule of Disaggregated Revenue	We disaggregate our net sales by product line and geographic location for each of our segments as we believe it best depicts how the nature, amount, timing and certainty of our net sales and cash flows are affected by economic factors. Net Sales by Product Line Three Months Six Months 2022 2021 2022 2021 MedSurg and Neurotechnology: Instruments $ 563 $ 517 $ 1,091 $ 986 Endoscopy 600 518 1,138 987 Medical 666 640 1,330 1,262 Neurovascular 306 301 607 590 Neuro Cranial 337 310 660 591 Other 77 73 146 134 $ 2,549 $ 2,359 $ 4,972 $ 4,550 Orthopaedics and Spine: Knees $ 500 $ 474 $ 964 $ 886 Hips 364 353 691 662 Trauma and Extremities 676 674 1,361 1,314 Spine 290 307 569 585 Other 114 127 211 250 $ 1,944 $ 1,935 $ 3,796 $ 3,697 Total $ 4,493 $ 4,294 $ 8,768 $ 8,247 Net Sales by Geography Three Months 2022 Three Months 2021 United States International United States International MedSurg and Neurotechnology: Instruments $ 451 $ 112 $ 401 $ 116 Endoscopy 473 127 407 111 Medical 536 130 488 152 Neurovascular 113 193 115 186 Neuro Cranial 281 56 256 54 Other 75 2 72 1 $ 1,929 $ 620 $ 1,739 $ 620 Orthopaedics and Spine: Knees $ 368 $ 132 $ 349 $ 125 Hips 230 134 221 132 Trauma and Extremities 489 187 475 199 Spine 209 81 217 90 Other 86 28 99 28 $ 1,382 $ 562 $ 1,361 $ 574 Total $ 3,311 $ 1,182 $ 3,100 $ 1,194 Net Sales by Geography Six Months 2022 Six Months 2021 United States International United States International MedSurg and Neurotechnology: Instruments $ 865 $ 226 $ 756 $ 230 Endoscopy 891 247 761 226 Medical 1,061 269 961 301 Neurovascular 223 384 226 364 Neuro Cranial 545 115 480 111 Other 143 3 132 2 $ 3,728 $ 1,244 $ 3,316 $ 1,234 Orthopaedics and Spine: Knees $ 713 $ 251 $ 643 $ 243 Hips 432 259 407 255 Trauma and Extremities 976 385 915 399 Spine 409 160 410 175 Other 158 53 193 57 $ 2,688 $ 1,108 $ 2,568 $ 1,129 Total $ 6,416 $ 2,352 $ 5,884 $ 2,363

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive (Loss) Income (AOCI) (Tables)	6 Months Ended
	Jun. 30, 2022
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss)	Three Months 2022 Marketable Securities Pension Plans Hedges Financial Statement Translation Total Beginning $ (1) $ (156) $ 41 $ (363) $ (479) OCI — 8 32 268 308 Income taxes — (2) (4) (98) (104) Reclassifications to: Cost of sales — — (3) — (3) Other (income) expense — 2 (1) (11) (10) Income taxes — — — 2 2 Net OCI $ — $ 8 $ 24 $ 161 $ 193 Ending $ (1) $ (148) $ 65 $ (202) $ (286) Three Months 2021 Marketable Securities Pension Plans Hedges Financial Statement Translation Total Beginning $ (3) $ (252) $ 18 $ (630) $ (867) OCI — (9) 7 (75) (77) Income taxes — 2 (3) 2 1 Reclassifications to: Cost of sales — — 4 — 4 Other (income) expense — 4 (1) (9) (6) Income taxes — (1) 1 2 2 Net OCI $ — $ (4) $ 8 $ (80) $ (76) Ending $ (3) $ (256) $ 26 $ (710) $ (943) Six Months 2022 Marketable Securities Pension Plans Hedges Financial Statement Translation Total Beginning $ — $ (155) $ 40 $ (416) $ (531) OCI (1) 4 36 354 393 Income taxes — — (6) (123) (129) Reclassifications to: Cost of sales — — (3) — (3) Other (income) expense — 4 (2) (22) (20) Income taxes — (1) — 5 4 Net OCI $ (1) $ 7 $ 25 $ 214 $ 245 Ending $ (1) $ (148) $ 65 $ (202) $ (286) Six Months 2021 Marketable Securities Pension Plans Hedges Financial Statement Translation Total Beginning $ (3) $ (259) $ (10) $ (885) $ (1,157) OCI — (1) 34 198 231 Income taxes — (2) (11) (10) (23) Reclassifications to: Cost of sales — — 5 — 5 Other (income) expense — 8 9 (17) — Income taxes — (2) (1) 4 1 Net OCI $ — $ 3 $ 36 $ 175 $ 214 Ending $ (3) $ (256) $ 26 $ (710) $ (943)
Reclassification out of Accumulated Other Comprehensive Income	Three Months 2022 Marketable Securities Pension Plans Hedges Financial Statement Translation Total Beginning $ (1) $ (156) $ 41 $ (363) $ (479) OCI — 8 32 268 308 Income taxes — (2) (4) (98) (104) Reclassifications to: Cost of sales — — (3) — (3) Other (income) expense — 2 (1) (11) (10) Income taxes — — — 2 2 Net OCI $ — $ 8 $ 24 $ 161 $ 193 Ending $ (1) $ (148) $ 65 $ (202) $ (286) Three Months 2021 Marketable Securities Pension Plans Hedges Financial Statement Translation Total Beginning $ (3) $ (252) $ 18 $ (630) $ (867) OCI — (9) 7 (75) (77) Income taxes — 2 (3) 2 1 Reclassifications to: Cost of sales — — 4 — 4 Other (income) expense — 4 (1) (9) (6) Income taxes — (1) 1 2 2 Net OCI $ — $ (4) $ 8 $ (80) $ (76) Ending $ (3) $ (256) $ 26 $ (710) $ (943) Six Months 2022 Marketable Securities Pension Plans Hedges Financial Statement Translation Total Beginning $ — $ (155) $ 40 $ (416) $ (531) OCI (1) 4 36 354 393 Income taxes — — (6) (123) (129) Reclassifications to: Cost of sales — — (3) — (3) Other (income) expense — 4 (2) (22) (20) Income taxes — (1) — 5 4 Net OCI $ (1) $ 7 $ 25 $ 214 $ 245 Ending $ (1) $ (148) $ 65 $ (202) $ (286) Six Months 2021 Marketable Securities Pension Plans Hedges Financial Statement Translation Total Beginning $ (3) $ (259) $ (10) $ (885) $ (1,157) OCI — (1) 34 198 231 Income taxes — (2) (11) (10) (23) Reclassifications to: Cost of sales — — 5 — 5 Other (income) expense — 8 9 (17) — Income taxes — (2) (1) 4 1 Net OCI $ — $ 3 $ 36 $ 175 $ 214 Ending $ (3) $ (256) $ 26 $ (710) $ (943)

Derivative Instruments (Tables)

Derivative Instruments (Tables)	6 Months Ended
	Jun. 30, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value	June 2022 Cash Flow Net Investment Non-Designated Total Gross notional amount $ 676 $ 1,578 $ 5,194 $ 7,448 Maximum term in years 4.4 Fair value: Other current assets $ 36 $ — $ 158 $ 194 Other noncurrent assets 2 150 — 152 Other current liabilities (4) — (10) (14) Total fair value $ 34 $ 150 $ 148 $ 332 December 2021 Cash Flow Net Investment Non-Designated Total Gross notional amount $ 973 $ 2,266 $ 5,512 $ 8,751 Maximum term in years 4.9 Fair value: Other current assets $ 15 $ 39 $ 92 $ 146 Other noncurrent assets 1 65 — 66 Other current liabilities (7) — (10) (17) Total fair value $ 9 $ 104 $ 82 $ 195
Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location	Derivative Three Months Six Months instrument: Recorded in: 2022 2021 2022 2021 Cash Flow Cost of sales $ 3 $ (4) $ 3 $ (5) Net Investment Other income (expense), net 11 9 22 17 Non-Designated Other income (expense), net 2 1 3 (1) Total $ 16 $ 6 $ 28 $ 11

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	Assets Measured at Fair Value June December 2022 2021 Cash and cash equivalents $ 1,044 $ 2,944 Trading marketable securities 160 193 Level 1 - Assets $ 1,204 $ 3,137 Available-for-sale marketable securities: Corporate and asset-backed debt securities $ 47 $ 48 Foreign government debt securities 2 2 United States agency debt securities 4 5 United States Treasury debt securities 27 19 Certificates of deposit 3 1 Total available-for-sale marketable securities $ 83 $ 75 Foreign currency exchange forward contracts 346 212 Level 2 - Assets $ 429 $ 287 Total assets measured at fair value $ 1,633 $ 3,424 Liabilities Measured at Fair Value June December 2022 2021 Deferred compensation arrangements $ 160 $ 193 Level 1 - Liabilities $ 160 $ 193 Foreign currency exchange forward contracts $ 14 $ 17 Level 2 - Liabilities $ 14 $ 17 Contingent consideration: Beginning $ 306 $ 393 Additions 1 62 Change in estimate (27) (1) Settlements (24) (148) Ending $ 256 $ 306 Level 3 - Liabilities $ 256 $ 306 Total liabilities measured at fair value $ 430 $ 516
Investments Classified by Contractual Maturity Date	Fair Value of Available for Sale Securities by Maturity June 2022 December 2021 Due in one year or less $ 52 $ 36 Due after one year through three years $ 31 $ 39

Contingencies and Commitments (

Contingencies and Commitments (Tables)	6 Months Ended
	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Lease, Cost	Leases June December 2022 2021 Right-of-use assets $ 469 $ 419 Lease liabilities, current $ 118 $ 112 Lease liabilities, non-current $ 353 $ 310 Other information: Weighted-average remaining lease term 5.6 years 5.4 years Weighted-average discount rate 2.66 % 2.86 % Three Months Six Months 2022 2021 2022 2021 Operating lease cost $ 38 $ 31 $ 73 $ 67

Acquisitions (Tables)

Acquisitions (Tables)	6 Months Ended
	Jun. 30, 2022
Business Combinations [Abstract]
Schedule of Business Acquisitions, by Acquisition	Purchase price allocations for our significant acquisitions are: Purchase Price Allocation of Acquired Net Assets 2022 Vocera Tangible assets and liabilities: Accounts receivable $ 33 Inventory 13 Deferred income tax assets 73 Other assets 92 Debt (425) Deferred income tax liabilities (182) Other liabilities (115) Intangible assets: Customer and distributor relationships 550 Developed technology and patents 178 Trade name 18 Goodwill 2,328 Purchase price, net of cash acquired of $281 $ 2,563 Weighted-average life of intangible assets 13
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	Consolidated Estimated Amortization Expense Remainder of 2022 2023 2024 2025 2026 $ 320 $ 620 $ 590 $ 570 $ 513

Debt and Credit Facilities (Tab

Debt and Credit Facilities (Tables)	6 Months Ended
	Jun. 30, 2022
Long-term Debt, Unclassified [Abstract]
Schedule of Long-term Debt Instruments	Summary of Total Debt June 2022 December 2021 Rate Due Senior unsecured notes: 1.125% November 30, 2023 $ 577 $ 622 0.600% December 1, 2023 598 598 3.375% May 15, 2024 595 593 0.250% December 3, 2024 890 958 1.150% June 15, 2025 646 645 3.375% November 1, 2025 748 748 3.500% March 15, 2026 994 994 2.125% November 30, 2027 784 845 3.650% March 7, 2028 597 597 0.750% March 1, 2029 836 901 1.950% June 15, 2030 990 990 2.625% November 30, 2030 675 727 1.000% December 3, 2031 779 840 4.100% April 1, 2043 392 392 4.375% May 15, 2044 395 395 4.625% March 15, 2046 982 982 2.900% June 15, 2050 642 642 Term loan February 22, 2025 1,250 — Other 11 10 Total debt $ 13,381 $ 12,479 Less current maturities of debt 7 7 Total long-term debt $ 13,374 $ 12,472 June 2022 December 2021 Unamortized debt issuance costs $ 57 $ 62 Borrowing capacity on existing facilities $ 2,162 $ 2,162 Fair value of senior unsecured notes $ 11,122 $ 13,391

Segment Information (Tables)

Segment Information (Tables)	6 Months Ended
	Jun. 30, 2022
Segment Reporting [Abstract]
Sales and Other Financial Information by Business Segment	Three Months Six Months 2022 2021 2022 2021 MedSurg and Neurotechnology $ 2,549 $ 2,359 $ 4,972 $ 4,550 Orthopaedics and Spine 1,944 1,935 3,796 3,697 Net sales $ 4,493 $ 4,294 $ 8,768 $ 8,247 MedSurg and Neurotechnology $ 601 $ 702 $ 1,212 $ 1,337 Orthopaedics and Spine 607 563 1,129 1,018 Segment operating income $ 1,208 $ 1,265 $ 2,341 $ 2,355 Items not allocated to segments: Corporate and other $ (145) $ (154) $ (344) $ (316) Acquisition and integration-related costs (37) (120) (186) (369) Amortization of intangible assets (160) (149) (310) (330) Restructuring-related and other charges (62) (17) (171) (31) Medical device regulations (32) (26) (60) (45) Recall-related matters (4) (76) (18) (82) Regulatory and legal matters 4 9 (33) 9 Consolidated operating income $ 772 $ 732 $ 1,219 $ 1,191

Revenue Recognition - Disaggreg

Revenue Recognition - Disaggregated Sales Analysis (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Disaggregation of Revenue [Line Items]
Net sales	$ 4,493	$ 4,294	$ 8,768	$ 8,247
United States
Disaggregation of Revenue [Line Items]
Net sales	3,311	3,100	6,416	5,884
International
Disaggregation of Revenue [Line Items]
Net sales	1,182	1,194	2,352	2,363
MedSurg and Neurotechnology:
Disaggregation of Revenue [Line Items]
Net sales	2,549	2,359	4,972	4,550
MedSurg and Neurotechnology: | United States
Disaggregation of Revenue [Line Items]
Net sales	1,929	1,739	3,728	3,316
MedSurg and Neurotechnology: | International
Disaggregation of Revenue [Line Items]
Net sales	620	620	1,244	1,234
MedSurg and Neurotechnology: | Instruments
Disaggregation of Revenue [Line Items]
Net sales	563	517	1,091	986
MedSurg and Neurotechnology: | Instruments | United States
Disaggregation of Revenue [Line Items]
Net sales	451	401	865	756
MedSurg and Neurotechnology: | Instruments | International
Disaggregation of Revenue [Line Items]
Net sales	112	116	226	230
MedSurg and Neurotechnology: | Endoscopy
Disaggregation of Revenue [Line Items]
Net sales	600	518	1,138	987
MedSurg and Neurotechnology: | Endoscopy | United States
Disaggregation of Revenue [Line Items]
Net sales	473	407	891	761
MedSurg and Neurotechnology: | Endoscopy | International
Disaggregation of Revenue [Line Items]
Net sales	127	111	247	226
MedSurg and Neurotechnology: | Medical
Disaggregation of Revenue [Line Items]
Net sales	666	640	1,330	1,262
MedSurg and Neurotechnology: | Medical | United States
Disaggregation of Revenue [Line Items]
Net sales	536	488	1,061	961
MedSurg and Neurotechnology: | Medical | International
Disaggregation of Revenue [Line Items]
Net sales	130	152	269	301
MedSurg and Neurotechnology: | Neurovascular
Disaggregation of Revenue [Line Items]
Net sales	306	301	607	590
MedSurg and Neurotechnology: | Neurovascular | United States
Disaggregation of Revenue [Line Items]
Net sales	113	115	223	226
MedSurg and Neurotechnology: | Neurovascular | International
Disaggregation of Revenue [Line Items]
Net sales	193	186	384	364
MedSurg and Neurotechnology: | Neuro Cranial
Disaggregation of Revenue [Line Items]
Net sales	337	310	660	591
MedSurg and Neurotechnology: | Neuro Cranial | United States
Disaggregation of Revenue [Line Items]
Net sales	281	256	545	480
MedSurg and Neurotechnology: | Neuro Cranial | International
Disaggregation of Revenue [Line Items]
Net sales	56	54	115	111
MedSurg and Neurotechnology: | Other
Disaggregation of Revenue [Line Items]
Net sales	77	73	146	134
MedSurg and Neurotechnology: | Other | United States
Disaggregation of Revenue [Line Items]
Net sales	75	72	143	132
MedSurg and Neurotechnology: | Other | International
Disaggregation of Revenue [Line Items]
Net sales	2	1	3	2
Orthopaedics and Spine:
Disaggregation of Revenue [Line Items]
Net sales	1,944	1,935	3,796	3,697
Orthopaedics and Spine: | United States
Disaggregation of Revenue [Line Items]
Net sales	1,382	1,361	2,688	2,568
Orthopaedics and Spine: | International
Disaggregation of Revenue [Line Items]
Net sales	562	574	1,108	1,129
Orthopaedics and Spine: | Other
Disaggregation of Revenue [Line Items]
Net sales	114	127	211	250
Orthopaedics and Spine: | Other | United States
Disaggregation of Revenue [Line Items]
Net sales	86	99	158	193
Orthopaedics and Spine: | Other | International
Disaggregation of Revenue [Line Items]
Net sales	28	28	53	57
Orthopaedics and Spine: | Knees
Disaggregation of Revenue [Line Items]
Net sales	500	474	964	886
Orthopaedics and Spine: | Knees | United States
Disaggregation of Revenue [Line Items]
Net sales	368	349	713	643
Orthopaedics and Spine: | Knees | International
Disaggregation of Revenue [Line Items]
Net sales	132	125	251	243
Orthopaedics and Spine: | Hips
Disaggregation of Revenue [Line Items]
Net sales	364	353	691	662
Orthopaedics and Spine: | Hips | United States
Disaggregation of Revenue [Line Items]
Net sales	230	221	432	407
Orthopaedics and Spine: | Hips | International
Disaggregation of Revenue [Line Items]
Net sales	134	132	259	255
Orthopaedics and Spine: | Trauma and Extremities
Disaggregation of Revenue [Line Items]
Net sales	676	674	1,361	1,314
Orthopaedics and Spine: | Trauma and Extremities | United States
Disaggregation of Revenue [Line Items]
Net sales	489	475	976	915
Orthopaedics and Spine: | Trauma and Extremities | International
Disaggregation of Revenue [Line Items]
Net sales	187	199	385	399
Orthopaedics and Spine: | Spine
Disaggregation of Revenue [Line Items]
Net sales	290	307	569	585
Orthopaedics and Spine: | Spine | United States
Disaggregation of Revenue [Line Items]
Net sales	209	217	409	410
Orthopaedics and Spine: | Spine | International
Disaggregation of Revenue [Line Items]
Net sales	$ 81	$ 90	$ 160	$ 175

Revenue Recognition - Narrative

Revenue Recognition - Narrative (Details) - USD ($) $ in Millions	Jun. 30, 2022	Dec. 31, 2021
Revenue Recognition [Abstract]
Contract liabilities	$ 640	$ 529

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive (Loss) Income (AOCI) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Accumulated Other Comprehensive Income (Loss), Net of Tax at beginning of period	$ (479)	$ (867)	$ (531)	$ (1,157)
OCI	308	(77)	393	231
Income taxes	(104)	1	(129)	(23)
Cost of sales	1,667	1,522	3,208	2,966
Other (income) expense	(52)	(70)	(113)	(162)
Income taxes	(64)	(70)	(127)	(135)
Net OCI	193	(76)	245	214
Accumulated Other Comprehensive Income (Loss), Net of Tax at end of period	(286)	(943)	(286)	(943)
Reclassification out of Accumulated Other Comprehensive Income
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Cost of sales	(3)	4	(3)	5
Other (income) expense	(10)	(6)	(20)	0
Income taxes	2	2	4	1
Net OCI	193	(76)	245	214
Marketable Securities
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Accumulated Other Comprehensive Income (Loss), Net of Tax at beginning of period	(1)	(3)	0	(3)
OCI	0	0	(1)	0
Income taxes	0	0	0	0
Accumulated Other Comprehensive Income (Loss), Net of Tax at end of period	(1)	(3)	(1)	(3)
Marketable Securities | Reclassification out of Accumulated Other Comprehensive Income
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Cost of sales	0	0	0	0
Other (income) expense	0	0	0	0
Income taxes	0	0	0	0
Net OCI	0	0	(1)	0
Pension Plans
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Accumulated Other Comprehensive Income (Loss), Net of Tax at beginning of period	(156)	(252)	(155)	(259)
OCI	8	(9)	4	(1)
Income taxes	(2)	2	0	(2)
Accumulated Other Comprehensive Income (Loss), Net of Tax at end of period	(148)	(256)	(148)	(256)
Pension Plans | Reclassification out of Accumulated Other Comprehensive Income
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Cost of sales	0	0	0	0
Other (income) expense	2	4	4	8
Income taxes	0	(1)	(1)	(2)
Net OCI	8	(4)	7	3
Hedges
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Accumulated Other Comprehensive Income (Loss), Net of Tax at beginning of period	41	18	40	(10)
OCI	32	7	36	34
Income taxes	(4)	(3)	(6)	(11)
Accumulated Other Comprehensive Income (Loss), Net of Tax at end of period	65	26	65	26
Hedges | Reclassification out of Accumulated Other Comprehensive Income
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Cost of sales	(3)	4	(3)	5
Other (income) expense	(1)	(1)	(2)	9
Income taxes	0	1	0	(1)
Net OCI	24	8	25	36
Financial Statement Translation
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Accumulated Other Comprehensive Income (Loss), Net of Tax at beginning of period	(363)	(630)	(416)	(885)
OCI	268	(75)	354	198
Income taxes	(98)	2	(123)	(10)
Accumulated Other Comprehensive Income (Loss), Net of Tax at end of period	(202)	(710)	(202)	(710)
Financial Statement Translation | Reclassification out of Accumulated Other Comprehensive Income
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Cost of sales	0	0	0	0
Other (income) expense	(11)	(9)	(22)	(17)
Income taxes	2	2	5	4
Net OCI	$ 161	$ (80)	$ 214	$ 175

Derivative Instruments (Forward

Derivative Instruments (Forward Currency Exchange Contracts) (Details) - Foreign Exchange Contract € in Millions, $ in Millions	3 Months Ended	6 Months Ended
	Mar. 31, 2022	Jun. 30, 2022 USD ($)	Jun. 30, 2022 EUR (€)	Dec. 31, 2021 USD ($)	Dec. 31, 2021 EUR (€)
Derivative [Line Items]
Notional Amount		$ 7,448		$ 8,751
Maximum term in years	4 years 10 months 24 days	4 years 4 months 24 days
Derivative, Fair Value, Net		$ 332		195
Other current assets
Derivative [Line Items]
Derivative assets		194		146
Other noncurrent assets
Derivative [Line Items]
Derivative assets		152		66
Other current liabilities
Derivative [Line Items]
Derivative liabilities		(14)		(17)
Net Investment
Derivative [Line Items]
Notional Amount | €			€ 4,400		€ 4,400
Non-Designated
Derivative [Line Items]
Notional Amount		5,194		5,512
Derivative, Fair Value, Net		148		82
Non-Designated | Other current assets
Derivative [Line Items]
Derivative assets		158		92
Non-Designated | Other noncurrent assets
Derivative [Line Items]
Derivative assets		0		0
Non-Designated | Other current liabilities
Derivative [Line Items]
Derivative liabilities		(10)		(10)
Cash Flow | Net Investment
Derivative [Line Items]
Notional Amount		676		973
Derivative, Fair Value, Net		34		9
Cash Flow | Net Investment | Other current assets
Derivative [Line Items]
Derivative assets		36		15
Cash Flow | Net Investment | Other noncurrent assets
Derivative [Line Items]
Derivative assets		2		1
Cash Flow | Net Investment | Other current liabilities
Derivative [Line Items]
Derivative liabilities		(4)		(7)
Net Investment | Net Investment
Derivative [Line Items]
Notional Amount		1,578		2,266
Derivative, Fair Value, Net		150		104
Net Investment | Net Investment | Other current assets
Derivative [Line Items]
Derivative assets		0		39
Net Investment | Net Investment | Other noncurrent assets
Derivative [Line Items]
Derivative assets		150		65
Net Investment | Net Investment | Other current liabilities
Derivative [Line Items]
Derivative liabilities		$ 0		$ 0

Derivative Instruments (Narrati

Derivative Instruments (Narrative) (Details) $ in Millions	6 Months Ended
	Jun. 30, 2022 USD ($)	Jun. 30, 2022 EUR (€)	Dec. 31, 2021 USD ($)	Dec. 31, 2021 EUR (€)
Foreign Exchange Contract
Notional amount	$ 7,448		$ 8,751
Designated as Hedging Instrument | Foreign Exchange Contract
Derivative, notional amount | €		€ 1,500,000,000		€ 2,000,000,000
Notional amount | €		€ 4,400,000,000		€ 4,400,000,000
Derivative, fair value	254
Cash flow hedge gain (loss) to be reclassified within twelve months	38
Net investment hedges expected to be reclassified to cost of sales and other income (expense)	32
Designated as Hedging Instrument | Interest Rate Swap
Cash flow hedge gain (loss) to be reclassified within twelve months	$ 5

Derivative Instruments (Income

Derivative Instruments (Income Statement Location) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Foreign Exchange Contract
Derivative Instruments, Gain (Loss) [Line Items]
Net currency exchange rate gains (losses)	$ 16	$ 6	$ 28	$ 11
Foreign Exchange Contract | Cost of sales
Derivative Instruments, Gain (Loss) [Line Items]
Net currency exchange rate gains (losses)	3	(4)	3	(5)
Foreign Exchange Contract | Other income (expense), net
Derivative Instruments, Gain (Loss) [Line Items]
Net currency exchange rate gains (losses)	2	1	3	(1)
Net Investment | Other income (expense), net
Derivative Instruments, Gain (Loss) [Line Items]
Net currency exchange rate gains (losses)	$ 11	$ 9	$ 22	$ 17

Fair Value Measurements (Valuat

Fair Value Measurements (Valuation Of Financial Instruments By Pricing Categories) (Details) - USD ($) $ in Millions	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	$ 1,044	$ 2,944
Assets
Available-for-sale securities, current	83	75
Investments Fair Value Disclosure	1,633	3,424
Contingent consideration:
Total liabilities measured at fair value	430	516
Fair Value, Inputs, Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	1,044	2,944
Trading marketable securities	160	193
Assets
Investments Fair Value Disclosure	1,204	3,137
Deferred compensation arrangements	160	193
Contingent consideration:
Total liabilities measured at fair value	160	193
Fair Value, Inputs, Level 2
Assets
Available-for-sale securities, current	83	75
Investments Fair Value Disclosure	429	287
Contingent consideration:
Total liabilities measured at fair value	14	17
Fair Value, Inputs, Level 2 | Foreign currency exchange forward contracts
Assets
Derivative asset	346	212
Liabilities
Foreign currency exchange forward contracts	14	17
Fair Value, Inputs, Level 2 | Corporate and asset-backed debt securities
Assets
Available-for-sale securities, current	47	48
Fair Value, Inputs, Level 2 | Foreign government
Assets
Available-for-sale securities, current	2	2
Fair Value, Inputs, Level 2 | United States agency debt securities
Assets
Available-for-sale securities, current	4	5
Fair Value, Inputs, Level 2 | United States Treasury debt securities
Assets
Available-for-sale securities, current	27	19
Fair Value, Inputs, Level 2 | Certificates of deposit
Assets
Available-for-sale securities, current	3	1
Fair Value, Inputs, Level 3
Contingent consideration:
Beginning	306	393
Additions	1	62
Change in estimate	(27)	(1)
Settlements	(24)	(148)
Ending	256	306
Total liabilities measured at fair value	$ 256	$ 306

Fair Value Measurements (Assets

Fair Value Measurements (Assets and Liabilities Measured At Fair Value On A Recurring Basis Using Unobservable Inputs (Level 3)) (Details) - USD ($) $ in Millions	Jun. 30, 2022	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Due in one year or less	$ 52	$ 36
Due after one year through three years	$ 31	$ 39

Fair Value Measurements (Narrat

Fair Value Measurements (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Fair Value Disclosures [Abstract]
Gain on sale of marketable securities	$ 20	$ 18	$ 35	$ 35

Contingencies and Commitments_2

Contingencies and Commitments (Narrative) (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended		6 Months Ended
	Mar. 31, 2022	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Loss Contingencies [Line Items]
Recall-related payments				$ (19)	$ (163)
Recall charges		$ 4	$ 76	18	$ 82
PureWick
Loss Contingencies [Line Items]
Charges during period	$ 28
Estimate of possible loss		100		100
Minimum
Loss Contingencies [Line Items]
Estimate of possible loss		380		380
Maximum
Loss Contingencies [Line Items]
Estimate of possible loss		$ 515		$ 515

Contingencies and Commitments -

Contingencies and Commitments - Leases (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Right-of-use assets	$ 469		$ 469		$ 419
Lease liabilities, current	118		118		112
Lease liabilities, non-current	$ 353		$ 353		$ 310
Other information:
Weighted-average remaining lease term	5 years 7 months 6 days		5 years 7 months 6 days		5 years 4 months 24 days
Weighted-average discount rate	2.66%		2.66%		2.86%
Operating lease cost	$ 38	$ 31	$ 73	$ 67

Acquisitions (Narrative) (Detai

Acquisitions (Narrative) (Details) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended	3 Months Ended	6 Months Ended
	Feb. 28, 2022	Jun. 30, 2022	Jun. 30, 2022	Jun. 30, 2021
Business Acquisition [Line Items]
Aggregate purchase price of acquisitions			$ 2,563	$ 108
Payments of long-term debt			$ 252	$ 1,151
Vocera
Business Acquisition [Line Items]
Aggregate purchase price of acquisitions	$ 2,600
Consideration transferred (in dollars per share)	$ 79.25
Business combination, consideration transferred, including convertible notes	$ 3,000
Share-based payment expense		$ 132
Vocera | 1.50% Convertible Notes
Business Acquisition [Line Items]
Stated interest rate		1.50%	1.50%
Payments of long-term debt			$ 101
Vocera | 0.50% Convertible Notes
Business Acquisition [Line Items]
Stated interest rate		0.50%	0.50%
Payments of long-term debt			$ 324

Acquisitions (Allocation Of The

Acquisitions (Allocation Of The Preliminary Purchase Price To The Acquired Net Assets (Details) - USD ($) $ in Millions	1 Months Ended	6 Months Ended
	Feb. 28, 2022	Jun. 30, 2022	Dec. 31, 2021
Goodwill		$ 15,115	$ 12,918
Vocera
Accounts receivable		33
Inventory		13
Deferred income tax assets		73
Other assets		92
Debt		(425)
Deferred income tax liabilities		(182)
Other liabilities		(115)
Goodwill		2,328
Purchase price, net of cash acquired of $281		$ 2,563
Weighted-average life of intangible assets		13 years
Cash acquired from acquisition	$ 281
Vocera | Customer and distributor relationships
Intangible assets acquired		$ 550
Vocera | Developed technology and patents
Intangible assets acquired		178
Vocera | Trade name
Intangible assets acquired		$ 18

Acquisitions (Future Amortizati

Acquisitions (Future Amortization Expense) (Details) $ in Millions	Jun. 30, 2022 USD ($)
Business Combinations [Abstract]
Remainder of 2022	$ 320
2023	620
2024	590
2025	570
2026	$ 513

Debt and Credit Facilities (Det

Debt and Credit Facilities (Details) - USD ($)	1 Months Ended		6 Months Ended
	Jun. 30, 2022	Feb. 28, 2022	Jun. 30, 2022	Dec. 31, 2021
Commercial paper	$ 0		$ 0
Borrowings outstanding under credit facility	0		0
Other Long-term Debt	11,000,000		11,000,000	$ 10,000,000
Total debt	13,381,000,000		13,381,000,000	12,479,000,000
Less current maturities of debt	7,000,000		7,000,000	7,000,000
Total long-term debt	13,374,000,000		13,374,000,000	12,472,000,000
Unamortized debt issuance costs	57,000,000		57,000,000	62,000,000
Borrowing capacity on existing facilities	2,162,000,000		2,162,000,000	2,162,000,000
Fair value of senior unsecured notes	11,122,000,000		$ 11,122,000,000	13,391,000,000
Term Loan
Debt instrument, face amount		$ 1,500,000,000
Repayments of debt	250,000,000
Maturity Date			Feb. 22, 2025
Long-term Debt	1,250,000,000		$ 1,250,000,000	0
Term Loan | SOFR
Basis spread on variable rate (as a percent)		0.725%
Credit Agreement | Revolving Credit Facility
Line of credit facility, maximum borrowing capacity	$ 2,250,000,000		$ 2,250,000,000	1,500,000,000
Senior Unsecured Notes 1.125% due 2021
Stated interest rate	1.125%		1.125%
Maturity Date			Nov. 30, 2023
Unsecured Debt	$ 577,000,000		$ 577,000,000	622,000,000
Senior Unsecured Notes, 0.600% Due 2023
Stated interest rate	0.60%		0.60%
Maturity Date			Dec. 01, 2023
Unsecured Debt	$ 598,000,000		$ 598,000,000	598,000,000
Senior Unsecured Notes 3.375% due 2024
Stated interest rate	3.375%		3.375%
Maturity Date			May 15, 2024
Unsecured Debt	$ 595,000,000		$ 595,000,000	593,000,000
Senior Unsecured Notes, 0.250% Due 2024
Stated interest rate	0.25%		0.25%
Maturity Date			Dec. 03, 2024
Unsecured Debt	$ 890,000,000		$ 890,000,000	958,000,000
Senior Unsecured Notes, 1.150% Due 2025
Stated interest rate	1.15%		1.15%
Maturity Date			Jun. 15, 2025
Unsecured Debt	$ 646,000,000		$ 646,000,000	645,000,000
Senior Unsecured Notes 3.375% due 2025
Stated interest rate	3.375%		3.375%
Maturity Date			Nov. 01, 2025
Unsecured Debt	$ 748,000,000		$ 748,000,000	748,000,000
Senior Unsecured Notes 3.50% due 2026
Stated interest rate	3.50%		3.50%
Maturity Date			Mar. 15, 2026
Unsecured Debt	$ 994,000,000		$ 994,000,000	994,000,000
Senior Unsecured Notes 2.125% due 2027
Stated interest rate	2.125%		2.125%
Maturity Date			Nov. 30, 2027
Unsecured Debt	$ 784,000,000		$ 784,000,000	845,000,000
Senior Unsecured Notes 3.650% due 2028
Stated interest rate	3.65%		3.65%
Maturity Date			Mar. 07, 2028
Unsecured Debt	$ 597,000,000		$ 597,000,000	597,000,000
Senior Unsecured Notes, 0.750% Due 2029
Stated interest rate	0.75%		0.75%
Maturity Date			Mar. 01, 2029
Unsecured Debt	$ 836,000,000		$ 836,000,000	901,000,000
Senior Unsecured Notes, 1.950% Due 2030
Stated interest rate	1.95%		1.95%
Maturity Date			Jun. 15, 2030
Unsecured Debt	$ 990,000,000		$ 990,000,000	990,000,000
Senior Unsecured Notes 2.625% due 2030
Stated interest rate	2.625%		2.625%
Maturity Date			Nov. 30, 2030
Unsecured Debt	$ 675,000,000		$ 675,000,000	727,000,000
Senior Unsecured Notes, 1.000% Due 2031
Stated interest rate	1%		1%
Maturity Date			Dec. 03, 2031
Unsecured Debt	$ 779,000,000		$ 779,000,000	840,000,000
Senior Unsecured Notes 4.100% due 2043
Stated interest rate	4.10%		4.10%
Maturity Date			Apr. 01, 2043
Unsecured Debt	$ 392,000,000		$ 392,000,000	392,000,000
Senior Unsecured Notes 4.375% due 2044
Stated interest rate	4.375%		4.375%
Maturity Date			May 15, 2044
Unsecured Debt	$ 395,000,000		$ 395,000,000	395,000,000
Senior Unsecured Notes 4.625% due 2046
Stated interest rate	4.625%		4.625%
Maturity Date			Mar. 15, 2046
Unsecured Debt	$ 982,000,000		$ 982,000,000	982,000,000
Senior Unsecured Notes, 2.900% due 2050
Stated interest rate	2.90%		2.90%
Maturity Date			Jun. 15, 2050
Unsecured Debt	$ 642,000,000		$ 642,000,000	$ 642,000,000
Commercial Paper
Debt instrument, maturity			397 days

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Tax [Abstract]
Effective income tax rate reconciliation, percent	8.90%	10.60%	11.50%	13.10%
Decrease in unrecognized tax positions is reasonably possible	$ 220		$ 220

Segment Information (Sales And

Segment Information (Sales And Other Financial Information By Business Segment) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Segment Reporting Information [Line Items]
Net sales	$ 4,493	$ 4,294	$ 8,768	$ 8,247
Segment operating income	772	732	1,219	1,191
Amortization of intangible assets	(160)	(149)	(310)	(330)
Recall-related matters	(4)	(76)	(18)	(82)
MedSurg and Neurotechnology:
Segment Reporting Information [Line Items]
Net sales	2,549	2,359	4,972	4,550
Orthopaedics and Spine:
Segment Reporting Information [Line Items]
Net sales	1,944	1,935	3,796	3,697
Operating Segments
Segment Reporting Information [Line Items]
Segment operating income	1,208	1,265	2,341	2,355
Operating Segments | MedSurg and Neurotechnology:
Segment Reporting Information [Line Items]
Net sales	2,549	2,359	4,972	4,550
Segment operating income	601	702	1,212	1,337
Operating Segments | Orthopaedics and Spine:
Segment Reporting Information [Line Items]
Net sales	1,944	1,935	3,796	3,697
Segment operating income	607	563	1,129	1,018
Corporate and other
Segment Reporting Information [Line Items]
Segment operating income	(145)	(154)	(344)	(316)
Segment Reconciling Items
Segment Reporting Information [Line Items]
Acquisition and integration-related costs	(37)	(120)	(186)	(369)
Amortization of intangible assets	(160)	(149)	(310)	(330)
Restructuring-related and other charges	(62)	(17)	(171)	(31)
Medical device regulations	(32)	(26)	(60)	(45)
Recall-related matters	(4)	(76)	(18)	(82)
Regulatory and legal matters	$ 4	$ 9	$ (33)	$ 9